BIIB: Biogen, Inc.
About
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.
Current Value
$155.031 Year Return
Current Value
$155.031 Year Return
Key Details
Market Cap
$22.65B
P/E Ratio
14.04
1Y Stock Return
-32.30%
1Y Revenue Growth
-3.98%
Dividend Yield
0.00%
Price to Book
1.4
Strategies that include BIIB
Stock's related to BIIB
Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| IPGP | 44.58% | $3.15B | -23.41% | 0.00% |
| RITM | 42.40% | $5.54B | +5.44% | 9.38% |
| XRAY | 42.29% | $3.75B | -39.08% | 3.32% |
| YORW | 42.13% | $514.17M | -3.87% | 2.37% |
| GT | 41.99% | $2.60B | -34.81% | 0.00% |
| SXT | 41.58% | $3.24B | +33.26% | 2.15% |
| AWK | 41.54% | $26.93B | +5.63% | 2.17% |
| CNS | 41.46% | $5.06B | +77.73% | 2.35% |
| TFX | 41.36% | $8.97B | -10.85% | 0.71% |
| INCY | 41.25% | $13.59B | +32.56% | 0.00% |
| JOE | 41.06% | $2.95B | -4.19% | 1.04% |
| AMGN | 40.94% | $150.48B | +6.52% | 3.20% |
| POR | 40.94% | $4.95B | +14.95% | 4.16% |
| NLY | 40.82% | $11.07B | +11.39% | 13.23% |
| CTS | 40.60% | $1.58B | +33.53% | 0.30% |
| FIBK | 40.42% | $3.49B | +33.95% | 5.62% |
| VC | 40.37% | $2.41B | -26.32% | 0.00% |
| DX | 39.94% | $991.29M | +9.75% | 12.54% |
| CCS | 39.79% | $2.69B | +20.00% | 1.19% |
| VSH | 39.76% | $2.07B | -31.61% | 2.64% |
Uncorrelated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| GRAL | -0.02% | $459.22M | -13.00% | 0.00% |
| LFVN | 0.10% | $169.84M | +130.61% | 1.10% |
| NTZ | -0.12% | $47.64M | -30.94% | 0.00% |
| VNOM | -0.19% | $5.48B | +79.62% | 3.35% |
| LITB | -0.21% | $35.48M | -75.45% | 0.00% |
| TXO | -0.23% | $737.26M | -1.80% | 13.22% |
| CRTO | -0.25% | $2.10B | +58.23% | 0.00% |
| IMNN | -0.25% | $10.02M | -22.89% | 0.00% |
| RNR | -0.29% | $13.74B | +23.09% | 0.58% |
| K | -0.34% | $27.77B | +52.50% | 2.79% |
| STVN | -0.34% | $4.95B | -32.48% | 0.32% |
| CCEC | -0.36% | $1.02B | +28.03% | 3.26% |
| CMG | 0.39% | $80.02B | +33.62% | 0.00% |
| EDU | -0.42% | $9.06B | -22.20% | 0.00% |
| AXS | -0.44% | $7.14B | +55.12% | 2.06% |
| QUAD | -0.46% | $366.66M | +43.76% | 2.84% |
| SCKT | -0.68% | $10.88M | +15.32% | 0.00% |
| NEUE | -0.71% | $40.93M | -34.13% | 0.00% |
| GL | 0.73% | $9.18B | -8.60% | 0.86% |
| EIG | -0.74% | $1.30B | +38.83% | 2.25% |
Inversely Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| GAN | -18.32% | $83.39M | +21.19% | 0.00% |
| KNSL | -17.92% | $10.93B | +29.38% | 0.13% |
| HUSA | -16.57% | $16.69M | -11.56% | 0.00% |
| TCTM | -13.92% | $8.10M | -42.99% | 0.00% |
| CPSH | -10.55% | $20.70M | -40.13% | 0.00% |
| PULM | -10.24% | $19.83M | +202.98% | 0.00% |
| VHC | -9.32% | $19.06M | -38.36% | 0.00% |
| KRRO | -8.97% | $436.84M | +20.68% | 0.00% |
| VZIO | -8.38% | $2.29B | +67.76% | 0.00% |
| PGR | -7.93% | $149.10B | +57.29% | 0.45% |
| BTCT | -7.73% | $42.61M | +353.33% | 0.00% |
| LUMO | -6.95% | $37.45M | +41.97% | 0.00% |
| NFLX | -6.55% | $372.45B | +83.46% | 0.00% |
| ROOT | -5.86% | $1.53B | +972.93% | 0.00% |
| MNR | -5.78% | $1.66B | -10.71% | 15.90% |
| WRB | -5.75% | $22.94B | +29.98% | 0.69% |
| ERIE | -5.57% | $19.39B | +46.23% | 1.23% |
| SAVA | -5.54% | $1.35B | +25.50% | 0.00% |
| MCK | -5.33% | $78.15B | +35.51% | 0.42% |
| STG | -5.27% | $35.67M | +7.92% | 0.00% |
ETF's related to BIIB
News
Yahoo
On Tuesday, UCB SA (OTC:UCBJY) (OTC:UCBJF) and Biogen Inc. (NASDAQ:BIIB) presented detailed results from the Phase 3 PHOENYCS GO study evaluating dapirolizumab pegol (DZP) for systemic lupus erythematosus. The drug candidate demonstrated significant clinical improvement in disease activity in patients with moderate-to-severe systemic lupus erythematosus (SLE). Also Read: Biogen/UCB Partnered Autoimmune Disease Candidate Hits Primary Goal In Late-Stage Study, Sets Stage Another Pivotal Trial The
Yahoo
We recently compiled a list of the 10 Best Genomics Stocks To Buy Right Now. In this article, we are going to take a look at where Biogen Inc. (NASDAQ:BIIB) stands against the other genomics stocks. Genomics is the study of genes and how they function. Many rapidly growing companies are emerging in the genomics field […]
Finnhub
Cambridge, MA, - - Biogen Inc. announced today that Alisha Alaimo, President, Head of North America, will participate in a fireside chat during the 7th Annual Evercore HealthCONx Conference. The...
Finnhub
INCHEON, CAMBRIDGE - Samsung Bioepis Co., Ltd. and Biogen Inc. today announced that the European Commission has approved OPUVIZ 40 mg/mL solution for injection in a vial, a biosimilar referencing...
Yahoo
Dapirolizumab pegol (DZP) met its primary endpoint, demonstrating statistically and clinically significant improvement across all organ systems as measured by BICLA, an endpoint measuring disease activityA greater response was observed across multiple clinical endpoints among participants treated with DZP including 50% less severe disease flares compared to participants on standard of care aloneSystemic Lupus Erythematosus is a chronic, debilitating autoimmune disease affecting multiple organ sy
Finnhub
UCB and Biogen announce that they have presented positive detailed results from the Phase 3 PHOENYCS GO study evaluating their dapirolizumab pegol in moderate-to-severe systemic lupus erythematosus...
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.